871657-49-7

Basic information

• Product Name: 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE
• Synonyms: 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE;3-(propan-2-yloxy)azetidine;Azetidine, 3-(1-Methylethoxy)-, hydrochloride;3-(1-Methylethoxy)-Azetidine hydrochloride;3-(propan-2-yloxy)azetidine hydrochloride
• CAS NO: 871657-49-7
• Molecular Formula: C₆H₁₃NO*ClH
• Molecular Weight: 151.63
• Mol File: 871657-49-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE(871657-49-7)
• EPA Substance Registry System: 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE(871657-49-7)

Safety Data

• Hazardous Substances Data: 871657-49-7(Hazardous Substances Data)

Usage

General Description

3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is a chemical compound that is commonly used as a building block in organic synthesis. It is a white to off-white crystalline powder that is soluble in water and organic solvents. 3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is known for its potential applications in the pharmaceutical industry, particularly in the development of new drugs and medications. It has been studied for its potential use in the treatment of various medical conditions, and its unique chemical structure makes it a valuable tool for researchers and chemists working in the field of drug discovery and development. Additionally, it may also have uses in other industries, such as in the production of specialty chemicals and advanced materials.

Relevant articles and documents

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.